ProTx-II

<strong>ProTx-II</strong> <strong>Catalog number:</strong> MDP0809 <strong>CAS Number: </strong>350670-85-8 <strong>Sequence: </strong>Tyr-Cys-Gln-Lys-Trp-Met-Trp-Thr-Cys-Asp-Ser-Glu-Arg-Lys-Cys-Cys-Glu-Gly-Met-Val-Cys-Arg-Leu-Trp-Cys-Lys-Lys-Lys-Leu-Trp (Disulfide bonds between Cys2-Cys16, Cys9-Cys21, and Cys15-Cys25) <strong>Amount:</strong> 100 ug <strong>Molecular Weight:</strong> 3826.4 g/mol <strong>Supplied as:</strong> Powder <strong>Applications:</strong> molecular tool for various biochemical applications <strong>Storage:</strong> -20 °C <strong>WARNING:</strong> For in vitro Research Use Only. NOT for use on humans or animals. <strong>Grade:</strong> Biotechnology grade. All products are highly pure. <strong>References:</strong> 1: Priest BT, Blumenthal KM, Smith JJ, Warren VA, Smith MM. ProTx-I and ProTx-II: gating modifiers of voltage-gated sodium channels Toxicon. 2007 Feb;49(2):194-201. 2: Adams GL, Pall PS, Grauer SM, Zhou X, Ballard JE, Vavrek M, Kraus RL, Morissette P, Li N, Colarusso S, Bianchi E, Palani A, Klein R, John CT, Wang D, Tudor M, Nolting AF, Biba M, Nowak T, Makarov AA, Reibarkh M, Buevich AV, Zhong W, Regalado EL, Wang X, Gao Q, Shahripour A, Zhu Y, de Simone D, Frattarelli T, Pasquini NM, Magotti P, Iaccarino R, Li Y, Solly K, Lee KJ, Wang W, Chen F, Zeng H, Wang J, Regan H, Amin RP, Regan CP, Burgey CS, Henze DA, Sun C, Tellers DM. Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Na(v)1.7 for the Treatment of Pain J Med Chem. 2022 Jan 13;65(1):485-496. 3: Schmalhofer WA, Calhoun J, Burrows R, Bailey T, Kohler MG, Weinglass AB, Kaczorowski GJ, Garcia ML, Koltzenburg M, Priest BT. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors Mol Pharmacol. 2008 Nov;74(5):1476-84. 4: Montnach J, De Waard S, Nicolas S, Burel S, Osorio N, Zoukimian C, Mantegazza M, Boukaiba R, Béroud R, Partiseti M, Delmas P, Marionneau C, De Waard M. Fluorescent- and tagged-protoxin II peptides: potent markers of the Na(v) 1.7 channel pain target Br J Pharmacol. 2021 Jul;178(13):2632-2650. 5: Li Y, North RY, Rhines LD, Tatsui CE, Rao G, Edwards DD, Cassidy RM, Harrison DS, Johansson CA, Zhang H, Dougherty PM. DRG Voltage-Gated Sodium Channel 1.7 Is Upregulated in Paclitaxel-Induced Neuropathy in Rats and in Humans with Neuropathic Pain J Neurosci. 2018 Jan 31;38(5):1124-1136. 6: Henriques ST, Deplazes E, Lawrence N, Cheneval O, Chaousis S, Inserra M, Thongyoo P, King GF, Mark AE, Vetter I, Craik DJ, Schroeder CI. Interaction of Tarantula Venom Peptide ProTx-II with Lipid Membranes Is a Prerequisite for Its Inhibition of Human Voltage-gated Sodium Channel NaV1.7 J Biol Chem. 2016 Aug 12;291(33):17049-65. 7: Tanaka K, Sekino S, Ikegami M, Ikeda H, Kamei J. Antihyperalgesic effects of ProTx-II, a Nav1.7 antagonist, and A803467, a Nav1.8 antagonist, in diabetic mice J Exp Pharmacol. 2015 Jun 24;7:11-6. 8: Xiao Y, Blumenthal K, Jackson JO 2nd, Liang S, Cummins TR. The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation Mol Pharmacol. 2010 Dec;78(6):1124-34. 9: Wright ZVF, McCarthy S, Dickman R, Reyes FE, Sanchez-Martinez S, Cryar A, Kilford I, Hall A, Takle AK, Topf M, Gonen T, Thalassinos K, Tabor AB. The Role of Disulfide Bond Replacements in Analogues of the Tarantula Toxin ProTx-II and Their Effects on Inhibition of the Voltage-Gated Sodium Ion Channel Na(v)1.7 J Am Chem Soc. 2017 Sep 20;139(37):13063-13075. <a href="https://pubmed.ncbi.nlm.nih.gov/30507158">10: Lawrence N, Wu B, Ligutti J, Cheneval O, Agwa AJ, Benfield AH, Biswas K, Craik DJ, Miranda LP, Henriques ST, Schroeder CI. Peptide-Membrane Interactions Affect the Inhibitory Potency and Selectivity of Spider Toxins ProTx-II and GpTx-1 ACS Chem Biol. 2019 Jan 18;14(1):118-130. </a> <br><strong>Products Related to ProTx-II can be found at</strong> <a href="https://moleculardepot.com/product-category/Peptides/"> Peptides</a>